1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sinsin Pharmaceutical Co., Ltd.

Sinsin Pharmaceutical Co., Ltd.

KKRX:002800
4,080.00
KRW
-75.00
(-1.81%)
883.70EPS
4.82P/E
64.93BMarket Cap
Sinsin Pharmaceutical Co., Ltd.
KRX:002800
(Korea Stock Exchange)

Recent

price

4,080.00

P/E

ratio

4.82

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
4,163.87
4,582.71
5,073.14
4,195.61
4,202.6
4,475.94
4,442.45
4,863.91
6,059.6
6,751.46
7,007.65
7,506.03
8,112.24
Revenue per Share
100
345
388
245
191
141
24
-97
291
308
322
613
887.76
Basic EPS, GAAP
-368.97
1.52
-404.87
67.79
-1,636.91
-1,649.76
-680.85
-174.76
291.28
-72.22
291.72
459.9
774.88
Free Cash Flow per Basic Share
10.79
10.74
21.14
27.32
33.02
33.02
28.11
- -
- -
49.92
59.96
60.05
- -
Dividend per Share
2,062.67
2,386.8
2,912.08
3,435.58
3,595.09
3,715.31
3,704.24
3,620.62
3,935.14
4,106.33
4,342.22
4,932.54
5,214.31
Book Value per Share
2,021.17
2,340.38
2,867.11
3,384.77
3,535.74
3,676.71
3,671.34
3,587.73
3,896.09
4,067.68
4,303.95
4,895.4
5,177.74
Tangible Book Value per Share
11
11
11
15
15
15
15
15
15
15
15
15
15
Basic Weighted Avg Shares
46,690
51,614
58,069
61,733
63,720
67,855
67,129
74,008
91,926
102,586
106,388
113,778
123,051
Sales/Revenue/Turnover
3.61
10.45
9.53
7.31
4.76
3.43
-6.21
-1.81
5.9
5.85
6.48
9.48
11.81
Operating Margin (%)
1,090
1,030
1,035
1,073
1,140
1,171
2,584
3,672
3,758
3,937
4,260
4,152
4,069
Depreciation Expense
1,121
3,886
4,441
3,605
2,896
2,138
363
-1,476
4,415
4,680
4,888
9,292
13,466
Net Income, GAAP
14.04
23.01
19.23
18.78
16.45
5.01
- -
- -
- -
- -
6.4
5.37
8.73
Effective Tax Rate (%)
2.4
7.53
7.65
5.84
4.54
3.15
0.54
-1.99
4.8
4.56
4.59
8.17
10.94
Profit Margin (%)
11,110
8,857
16,771
23,623
14,083
9,807
5,297
2,548
2,720
-4,612
-7,608
-942
4,082
Working Capital
9,778
4,148
11,193
3,247
17,358
33,528
26,985
24,810
18,926
9,902
3,937
1,264
752
LT Debt
24,387
28,219
34,430
52,313
54,655
56,371
56,048
54,800
59,531
62,090
65,569
74,520
78,737
Total Equity
- -
9.84
9.36
6.49
3.52
2.3
- -
- -
- -
- -
5.91
8.86
11.29
Return on Invested Capital (%)
- -
9.92
10
6.95
4.38
2.57
- -
- -
- -
- -
6.25
9.46
12.67
Return on Capital (%)
- -
14.77
14.18
8.33
5.43
3.85
0.64
-2.66
7.7
7.67
7.63
13.21
18.28
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
42,430
39,971
39,324
LT Borrowings
1,209
840
630
LT Finance Leases
55
35
122
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
88,899
81,314
64,930

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
59,420
63,234
64,435
Cash, Cash Equivalents & STI
3,876
4,373
2,983
Accounts Receivable, Net
32,808
34,312
35,669
Inventories
19,976
21,268
21,958
Total Current Liabilities
60,363
62,330
60,353
Payables & Accruals
- -
- -
- -
ST Debt
42,430
39,971
39,324
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.1%
5.99%
13.65%
Free Cash Flow
-3,090.97%
-182.27%
57.41%
Net Income, GAAP
-93.89%
-161.11%
90.08%
Sales/Revenue/Turnover
8.42%
11.34%
6.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
24,710
29,457
26,957
25,264
106,388
2025
25,310
29,597
30,115
28,757
113,778
2026
30,180
33,999
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
24
180
71
46.48
322
2025
66
90
225.55
230.44
613
2026
188.78
243
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
59.96
2025
- -
- -
- -
- -
60.05
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sinsin Pharmaceutical Co., Ltd. is a South Korea-based pharmaceutical company primarily engaged in the research, development, manufacturing, and commercialization of over-the-counter (OTC) medications, prescription pharmaceuticals, medical devices, and consumer healthcare products specializing in transdermal drug delivery systems (TDDS). Founded in 1959 and headquartered in Sejong, South Korea, with research and administrative operations centered at its Magok R&D Center in Seoul, the company distributes its products domestically to wholesale distributors, hospitals, and retail pharmacies, while maintaining export operations across North America, Central and South America, Southeast Asia, and Greater China. The company organizes its product offerings across therapeutic and consumer categories; its core portfolio includes topical analgesic and anti-inflammatory transdermal patches under flagship brand names such as Sinsin Pas, Sinsin Pas Arex, and Sinsin Pas RX; liquid roll-on analgesics including Mulpas; aerosol pain-relief sprays, ointments, lotions, and gels; wound care and first-aid supplies comprising hydrocolloid bandages, adhesive plasters, and surgical tapes; topical antifungal agents; anti-itch and insect bite remedies; insect repellent sprays; and pediatric cooling sheets. In recent operational and strategic developments, Sinsin Pharmaceutical has accelerated its transformation into a specialized biotechnology and drug delivery enterprise by advancing proprietary transdermal and microneedle therapeutic pipelines, including the clinical advancement of UIP-620, a transdermal patch treatment for overactive bladder, and SS-262, a patch formulation for insomnia, alongside the development of dissolvable and coated microneedle applications for obesity and alopecia. Additionally, the company has completed major automation and efficiency upgrades at its main Sejong manufacturing plant to support margin expansion, broadened its overseas regulatory and distribution footprint in international markets, and strengthened executive governance through leadership realignments to concentrate capital and research capabilities on its core TDDS pharmaceutical technologies.